title: Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.
abstract: Haematological features of 64 patients suffering from non operable cyanotic congenital heart disease (CCHD) treated with hydroxyurea (HU) were compared with those of 43 patients suffering from the same disorder who had not yet received this drug. Patients with subclinical renal dysfunction were excluded by measuring plasma creatinine levels. MCV and HbF were higher among patients receiving HU, the increase in MCV being cumulative with HU dosage but the rise in HbF dose independent. HbF response to HU was found to be due to the coordinated increase in F-cell and F-reticulocyte production rather than to a selective survival of F-cells. Absence of a relationship between plasma erythropoietin and HbF levels excluded a dominant role of the former in increasing F-cell production and results determined after doubling the HU dosage or immediately after initiating therapy suggested genetic differences to be responsible for the individual variations in Hb F response. No irreversible toxic effects or malignancies were noted in this series of patients. HU was administered for a relatively long period of time, the mean duration of treatment exceeding 5 years, while the study also included patients below the age of 10 years.
authors.affiliation: Laboratoire d'Hématologie, Hôpital Necker-Enfants Malades, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Triadou
authors.forename: M
authors.initials: M
authors.lastname: Maier-Redelsperger
authors.forename: R
authors.initials: R
authors.lastname: Krishnamoorty
authors.forename: A
authors.initials: A
authors.lastname: Deschamps
authors.forename: N
authors.initials: N
authors.lastname: Casadevall
authors.forename: O
authors.initials: O
authors.lastname: Dunda
authors.forename: R
authors.initials: R
authors.lastname: Ducrocq
authors.forename: J
authors.initials: J
authors.lastname: Elion
authors.forename: R
authors.initials: R
authors.lastname: Girot
authors.forename: D
authors.initials: D
authors.lastname: Labie
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003490:Cyanosis; D015672:Erythroid Precursor Cells / Q000187:drug effects; D004921:Erythropoietin / Q000097:blood; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis* / Q000235:genetics; D005914:Globins / Q000235:genetics; D006330:Heart Defects, Congenital / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D006400:Hematocrit; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D012150:Polymorphism, Restriction Fragment Length; D012189:Retrospective Studies
chemical_list: D004921:Erythropoietin; D005914:Globins; D005319:Fetal Hemoglobin; D010100:Oxygen; D006918:Hydroxyurea